TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Survival at 1 Year Post-Cultured Thymus Tissue Implantation
Endpoint domain: Mortality/survival
Primary endpoint: Safety assessed using adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of PWID Who Initiated ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Acute Success Post CartoFinder Guided Ablation (CFGA) Only
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Recurrence of Atrial Fibrillation, Atrial Flutter, and Atrial Tachycardia Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diagnostic power of LSCI and pinprick sensory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment of neutrophils by day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Current-graft versus host disease (GVHD)-free, relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number and types of problems discussed during visit
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of subjects with intracuff pressure within specified range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of nasal signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reproducibility of the kpl measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of the normalized area under the lactate curve (nLac)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete response (CR/CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Vaginal Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in using home tonometer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Terminal half-life of plasma FVIIa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma FVIIa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postnatal depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain at 1 hour postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 6 hours postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 1 day postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Accuracy of Three Rings Vulvoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response defined as 50% reduction in MADRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission defined as MADRS ≤ 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Existential Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduced BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduced hA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduced cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disability index in inflammatory bowel disease
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Patients Achieving 10-point Improvement in KOOS-Child Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of enrichment of 13-Carbon molecules in TCA cycle metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: continued negative sputum culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of voluntary medical male circumcision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Victorian Institute of Sport Assessment-Patellar (VISAP) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in International Knee Documentation Committee (IKDC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee Injection Questionnaire Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nasal NO level in parts per billion (ppb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average change in BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IgA levels in the bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inter-rater reliability of myotonometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between myotonometric measurement and isokinetic measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of distinguishing the localisation of myofascial trigger points within the taut band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing Depth Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Attachment Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunization Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Smoking Abstinence Weeks 3 to 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Abstinence Weeks 9 to 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Canadian Neurological Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with radiologic evidence of fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural response to photographs of the partner
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural response during the regulation of food craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Best PEEP level based on driving pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best PEEP level based on oxygenation (PaO2/FiO2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 2-year incidence of tumor recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative pancreatic fistula rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Day 30 Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Quality of driving take-over behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of ovarian follicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Prevalence of exercise-induced bronchoconstriction (EIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cancer related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Assessment in Dementia (DAD)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychosocial functioning I
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Selfharming behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Wound Healing Rate (Re-epithelialization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating surrogate markers of atherosclerosis for vascular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in Metabolic Syndrome (MetS) -Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Anterior circumflex humeral artery peak systolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anterior circumflex humeral artery resistive index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mass spectrometry measurement of C13 labelled proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of acute treatment related to diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduction of chronic treatment related to enteropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Unexplained local and systemic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and nature of participants with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD)/Recommended Phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Anti-PReferentially Expressed Antigen of MElanoma (Anti-PRAME) Humoral Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Best Overall Response to Study Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation during proprioceptive signal processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proprioceptive use during postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cytoplasmic p-MAPK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection/quantification of T. gondii IgG and IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Migraine Days Per Month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Resting high frequency heart rate variability (HF-HRV) at 12 months after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Useful Field of View test performance at 12 months after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Emotional well-being at 12 months after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intraoperative Remifentanil dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seasonal burden of Plasmodium falciparum infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pregnancy-Related Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Concentration (Tmax) of Oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of Oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tidal Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Driving Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Peak Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Mechanical Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Partial Pressure of Arterial Oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Partial Pressure of Arterial CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: morbidity after tonsillectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-month progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Taking Greater Than 1200 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Vasomotor Rhinitis Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malaria attack during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hospitalizations for specified cardiac reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Maladaptive Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of extramedullary myeloid leukemia (EML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean trough sitting systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Giardia antigen test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: morphology changes improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Coefficient of Fat Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oocyte Survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved scores on the Sydenham chorea assessment charts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FDG-PET signal indicating inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in FDG-PET signal indicating a change in neuronal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in EEG activity indicating a change in neuronal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 24h pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS QoL (Visual Analogue Scale - Quality of Life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Operating Room Efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of success to complete the full treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental area under the triglyceride curve (iAUC-TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body fat (% fat mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rescue medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ureteric Stent Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Histological NASH Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in urine flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Discontinuation due to an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change of lesion detection number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of GW572016 and Topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects of GW572016 and Topotecan
Endpoint domain: Adverse events/effects
Primary endpoint: Number of device related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of subjects who improved by 50% or more in ABL (FI episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who are progression free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum quetiapine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in saliva production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine increase or urine output decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MDS-UPDRS III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall Frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Global heart function measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Functional Ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients requiring uptitration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of influenza A virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Choline metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Newborn in Need of Respiratory Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Motor-evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intracortical facilitation assessed by transcranial magnetic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Short-interval intracortical inhibition assessed by transcranial magnetic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reaction times of action execution blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sutter-Eyberg Student Behavior Inventory (SESBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Competence Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pharmacokinetic parameters of prednisone/prednisolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of daunorubicin hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of vincristine sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Catheter-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Dropped Out of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of appropriate defibrillator therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Air Nicotine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of new conduction disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clear margins on histopathological sections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of Post-reperfusion pulmonary injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients suffering any kind of adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Experience a Grade 3-4 Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Response Rate to This Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes